3.
Groups cases defined by molecular biomarkers | Group 1 (n = 258) | Group 2 (n = 29) | Group 3 (n = 41) | Group 4 (n = 100) | P |
*P<0.05 was considered as significant.
*a Comparison of Group 3 with other groups. *b Comparison among groups with significant differences of APA in Group 3&4, MPP in Group 2, SPA in Group 2&3 and IMA in Group 4. Abbreviations: PD-L1, programmed death-ligand 1; MIA, minimally invasive adenocarcinoma; LPA, lepidic predominant adenocarcinoma; PPA, papillary predominant adenocarcinoma; APA, acinar predominant adenocarcinoma; MPA, micropapillary predominant adenocarcinoma; SPA, solid predominant adenocarcinoma; IMA, invasive mucinous adenocarcinoma. | |||||
PD-L1 expression | 0 | 29 | 41 | 0 | |
EGFR | 252 | 0 | 35 | 0 | |
ALK | 6 | 0 | 5 | 0 | |
ROS-1 | 2 | 0 | 1 | 0 | |
KRAS | 0 | 8 | 0 | 26 | |
Age (range, median) | 32−80, 60 | 45−79, 64 | 32−78, 57 | 33−83, 62 | < 0.001*a |
Gender | < 0.001*a | ||||
Male | 102 | 22 | 14 | 49 | |
Female | 196 | 7 | 27 | 51 | |
Smoking status | < 0.001*a | ||||
Yes | 221 | 8 | 12 | 42 | |
No | 77 | 21 | 29 | 58 | |
TNM stage | 0.005*a | ||||
I-II | 236 | 25 | 27 | 89 | |
III-IV | 62 | 6 | 16 | 13 | |
Histopathologic pattern | < 0.001*b | ||||
MIA | 11 | 1 | 1 | 5 | |
LPA | 41 | 0 | 1 | 11 | |
APA | 178 | 11 | 25 | 64 | |
PPA | 41 | 4 | 3 | 12 | |
MPP | 14 | 4 | 0 | 5 | |
SPA | 13 | 9 | 11 | 3 | |
IMA | 0 | 0 | 0 | 10 |